Core Viewpoint - FMC Corporation's stock has significantly declined following poor Q3 earnings and continued challenges in Q4, leading to a cautious outlook for investors [1][2]. Financial Performance - Q3 earnings revealed a 49% drop in sales, resulting in a loss of $4.52 per share, and a full-year revenue decline of 18% in 2025 [1][5]. - Q4 earnings missed revenue expectations, with management forecasting a further 5% decline in revenue to approximately $3.7 billion in 2026 and a 41% decline in adjusted EBITDA [2][8]. Stock Performance - Since the Q3 earnings report, FMC stock has stabilized, trading between $13 and $17, currently priced around $14.50 [3][8]. - The market capitalization of FMC is approximately $1.8 billion, with a current price-to-free cash flow ratio of 30 times, indicating a potentially expensive valuation given the debt load [8][9]. Strategic Options - FMC is exploring strategic options to maximize shareholder value, including the potential sale of the company [6]. - The company plans to raise $1 billion through asset sales and licensing agreements to reduce its debt, which currently exceeds cash by $3.5 billion [6]. Product Development - FMC is set to commercialize four new herbicides and fungicides, which may contribute to future revenue growth [7].